| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Z Safferman, J M Kane, J S Aronowitz, M F Gordon, S Pollack, J A Lieberma. The use of clozapine in neurologic disorders. The Journal of clinical psychiatry. vol 55 Suppl B. 1994-11-28. PMID:7961585. |
in general, clozapine doses used in these settings are lower than that for treating psychosis in schizophrenia. |
1994-11-28 |
2023-08-12 |
Not clear |
| B A Malow, K B Reese, S Sato, P J Bogard, A K Malhotra, T P Su, D Picka. Spectrum of EEG abnormalities during clozapine treatment. Electroencephalography and clinical neurophysiology. vol 91. issue 3. 1994-10-20. PMID:7522149. |
clozapine is a novel antipsychotic agent effective in treating refractory schizophrenia. |
1994-10-20 |
2023-08-12 |
Not clear |
| D Marinkovic, I Timotijevic, T Babinski, S Totic, V R Paunovi. The side-effects of clozapine: a four year follow-up study. Progress in neuro-psychopharmacology & biological psychiatry. vol 18. issue 3. 1994-10-06. PMID:8078987. |
clozapine, as the model agent for the atypical antipsychotic drugs, is currently recommended as effective regarding negative symptoms of schizophrenia and treatment-resistant schizophrenic patients. |
1994-10-06 |
2023-08-12 |
Not clear |
| M Maes, H Y Meltzer, E Bosman. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta psychiatrica Scandinavica. vol 89. issue 5. 1994-09-22. PMID:8067274. |
immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. |
1994-09-22 |
2023-08-12 |
human |
| M Maes, H Y Meltzer, E Bosman. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta psychiatrica Scandinavica. vol 89. issue 5. 1994-09-22. PMID:8067274. |
the purpose of this study was to investigate immune-inflammatory markers in schizophrenia and the effects of chronic treatment with clozapine, an atypical antipsychotic agent, on these variables. |
1994-09-22 |
2023-08-12 |
human |
| M Maes, H Y Meltzer, E Bosman. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta psychiatrica Scandinavica. vol 89. issue 5. 1994-09-22. PMID:8067274. |
we conclude that: (a) schizophrenia in younger people is accompanied by increased il-6 and sil-2r secretion; and (b) subchronic treatment with clozapine increases sil-2r levels. |
1994-09-22 |
2023-08-12 |
human |
| H Mok, L N Yatha. Response to clozapine as a predictor of risperidone response in schizophrenia. The American journal of psychiatry. vol 151. issue 9. 1994-09-16. PMID:7520672. |
response to clozapine as a predictor of risperidone response in schizophrenia. |
1994-09-16 |
2023-08-12 |
Not clear |
| K E Towbin, E M Dykens, R G Puglies. Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome. Journal of the American Academy of Child and Adolescent Psychiatry. vol 33. issue 5. 1994-09-12. PMID:7520035. |
clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome. |
1994-09-12 |
2023-08-12 |
Not clear |
| K E Towbin, E M Dykens, R G Puglies. Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome. Journal of the American Academy of Child and Adolescent Psychiatry. vol 33. issue 5. 1994-09-12. PMID:7520035. |
additional features of the case are the early social and developmental delays preceding schizophrenia, the response of symptoms of childhood-onset schizophrenia to clozapine, and the reduction in tardive dyskinesia symptoms while taking clozapine. |
1994-09-12 |
2023-08-12 |
Not clear |
| L K Jacobsen, M C Walker, J E Edwards, P B Chappell, J L Woolsto. Clozapine in the treatment of a young adolescent with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry. vol 33. issue 5. 1994-09-12. PMID:8056727. |
clozapine in the treatment of a young adolescent with schizophrenia. |
1994-09-12 |
2023-08-12 |
Not clear |
| J A Frazier, C T Gordon, K McKenna, M C Lenane, D Jih, J L Rapopor. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry. vol 33. issue 5. 1994-09-12. PMID:8056728. |
an open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. |
1994-09-12 |
2023-08-12 |
Not clear |
| J A Frazier, C T Gordon, K McKenna, M C Lenane, D Jih, J L Rapopor. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry. vol 33. issue 5. 1994-09-12. PMID:8056728. |
to review the response of 11 adolescents with childhood-onset schizophrenia to a 6-week open clozapine trial. |
1994-09-12 |
2023-08-12 |
Not clear |
| J M Vanelle, J P Olié, P Lévy-Soussa. New antipsychotics in schizophrenia: the French experience. Acta psychiatrica Scandinavica. Supplementum. vol 380. 1994-09-01. PMID:7914051. |
in france, in most cases, the indication of clozapine is still refractory paranoid schizophrenia. |
1994-09-01 |
2023-08-12 |
Not clear |
| E Klieser, W H Strauss, W Lemme. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta psychiatrica Scandinavica. Supplementum. vol 380. 1994-09-01. PMID:8048341. |
the tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. |
1994-09-01 |
2023-08-12 |
Not clear |
| A Fitton, P Benfiel. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. PharmacoEconomics. vol 4. issue 2. 1994-08-25. PMID:10146973. |
clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. |
1994-08-25 |
2023-08-12 |
Not clear |
| A Fitton, P Benfiel. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. PharmacoEconomics. vol 4. issue 2. 1994-08-25. PMID:10146973. |
thus, clozapine is effective against both the positive and negative symptoms of schizophrenia and has a low propensity to cause extrapyramidal effects. |
1994-08-25 |
2023-08-12 |
Not clear |
| A Fitton, P Benfiel. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. PharmacoEconomics. vol 4. issue 2. 1994-08-25. PMID:10146973. |
although the acquisition cost of clozapine is high in comparison with that of standard antipsychotics, preliminary cost-effectiveness estimates in patients with treatment-resistant schizophrenia suggest that the clinical benefits of the drug (viz. |
1994-08-25 |
2023-08-12 |
Not clear |
| L R Drew, M M Wood, R T Wa. Initial experiences with clozapine at Kenmore Psychiatric Hospital. The Medical journal of Australia. vol 161. issue 3. 1994-08-16. PMID:8035723. |
to replicate overseas experience with clozapine, a new antipsychotic drug reputed to be effective in producing major improvement in a high proportion of patients with treatment-resistant schizophrenia. |
1994-08-16 |
2023-08-12 |
Not clear |
| R A Dickson, R Williams, J T Dalb. The use of chloral hydrate and sodium amytal during clozapine initiation. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 39. issue 3. 1994-08-15. PMID:8033016. |
the effectiveness of alternate agents sodium amytal and chloral hydrate when initiating clozapine was evaluated in a group of 15 patients suffering from schizophrenia. |
1994-08-15 |
2023-08-12 |
Not clear |
| I Jalenques, A J Couder. [A new therapeutic approach tp drug-resistant schizophrenia: clozapine. Long-term prospective study in 16 patients]. Acta psychiatrica Belgica. vol 92. issue 6. 1994-08-11. PMID:1364281. |
[a new therapeutic approach tp drug-resistant schizophrenia: clozapine. |
1994-08-11 |
2023-08-11 |
Not clear |